// App-Quantinova.ai

517 : Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).

Researchers

Presenter

  • Miguel Martin

Principal Investigators

  • Sung-Bae Kim

  • Michael Schenker

  • Daniela Grecea

  • Jos A. Garca-Senz

  • Konstantinos Papazisis

  • Quchang Ouyang

  • Aleksandra Lacko

  • Berna Oksuzoglu

  • James Andrew Reeves

  • Meena Okera

  • Laura Testa

  • Chikako Shimizu

  • Ran Wei

  • Tammy D Forrester

  • Maria Munoz

  • Annamaria H. Zimmermann

  • Desiree Headley

  • Stephen R. D. Johnston

Medical Centers

  • Hospital Universitario Quiron Madrid, Madrid, Spain

  • University of Sao Paulo, Sao Paulo, Brazil

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • Centrul de Oncologie Sf Nectarie, Craiova, Romania

  • Cancer Institute I Chiricuta, Cluj, Romania

  • Euromedica General Clinic, Thessaloniki, Greece

  • Department of Medical Oncology, Zhejiang Cancer Hospital, Zhejiang, China

  • Dolnoslaskie Centrum Onkologii, Wroclawski Uniwersytet Medyczny, Wroclaw, Poland

  • Department of Medical Oncology, University of Health Sciences, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, TN, Turkey

  • Florida Cancer Specialists South/Sarah Cannon Research Institute, Fort Myers, FL, Ashford Cancer Center, Adelaide, Australia

  • Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, Brazil

  • Breast Center, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan

  • Eli Lilly and Company, Indianapolis, IN, Eil Lilly and Company, Indianapolis, IN, The Royal Marsden NHS Foundation Trust, London, United Kingdom

Locations

  • Spain

  • Brazil

  • Romania

  • Greece

  • China

  • Poland

  • Turkey

  • Australia

  • Japan

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Abemaciclib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT03155997

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved